Highlights and Quick Summary
- Weighted Average Shares Growth for the quarter ending March 31, 2022 was 66.68% (a -99.02% decrease compared to previous quarter)
- Year-over-year quarterly Weighted Average Shares Growth decreased by -99.21%
- Annual Weighted Average Shares Growth for 2021 was 7867.02% (a 14079.92% increase from previous year)
- Annual Weighted Average Shares Growth for 2020 was 55.48% (a -155.89% decrease from previous year)
- Annual Weighted Average Shares Growth for 2019 was -99.27% (a -Infinity% decrease from previous year)
Visit stockrow.com/TERN
for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow
statement with 10 years of data, and state-of-the-art screener.
Historical Weighted Average Shares Growth of Terns Pharmaceuticals, Inc.
Most recent Weighted Average Shares Growthof TERN including historical data for past 10 years.Interactive Chart of Weighted Average Shares Growth of Terns Pharmaceuticals, Inc.
Terns Pharmaceuticals, Inc. Weighted Average Shares Growth for the past 10 Years (both Annual and Quarterly)
| Year | Q1 | Q2 | Q3 | Q4 | Fiscal Year |
|---|---|---|---|---|---|
| 2022 | 66.68% | – | – | – | – |
| 2021 | 6801.52% | 8227.15% | 8469.97% | 6918.52% | 7867.02% |
| 2020 | -0.57% | -98.8% | -98.83% | -99.14% | 55.48% |
| 2019 | – | – | – | – | -99.27% |
| 2018 | – | – | – | – | 0.0% |
Business Profile of Terns Pharmaceuticals, Inc.
Sector: Healthcare
Industry: Biotechnology
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.